HIGHLIGHTS
SUMMARY
This work has served as the basis for the traditional approach for recombinant VACV rescue, which involves the infection of cells with a parental virus and simultaneous delivery of a donor template for homologous recombination, usually in the form of plasmid or PCR product. The capacity of an oncolytic VACV-based vector to generate STING agonists in situ in an oncoselective fashion should circumvent these limitations, enabling effective systemic delivery of STING agonists to the cancer cell. Lentivirus was generated by transfecting use Lenti-X 293T_cell line (Takarabio) by transfecting cells with pCMV-TO . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.